QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
QQQ   281.68 (-2.07%)
AAPL   142.91 (-2.54%)
MSFT   245.12 (-2.03%)
META   114.12 (-6.79%)
GOOGL   96.98 (-2.51%)
AMZN   88.25 (-3.03%)
TSLA   179.82 (-1.44%)
NVDA   159.87 (-3.75%)
NIO   13.24 (+3.44%)
BABA   91.45 (+1.03%)
AMD   70.27 (-4.55%)
T   19.17 (+2.24%)
MU   53.68 (-0.67%)
CGC   3.61 (-16.44%)
F   13.28 (-0.75%)
GE   85.28 (+0.73%)
DIS   92.29 (-3.79%)
AMC   6.75 (-9.40%)
PYPL   72.23 (-1.89%)
PFE   49.71 (-2.01%)
NFLX   305.56 (-2.25%)
NASDAQ:FDMT

4D Molecular Therapeutics - FDMT Stock Forecast, Price & News

$21.81
-1.36 (-5.87%)
(As of 12/6/2022 12:00 AM ET)
Add
Compare
Today's Range
$21.76
$23.37
50-Day Range
$6.85
$24.17
52-Week Range
$5.32
$24.99
Volume
284,007 shs
Average Volume
309,353 shs
Market Capitalization
$706.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$34.50

4D Molecular Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
58.2% Upside
$34.50 Price Target
Short Interest
Healthy
8.34% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.75mentions of 4D Molecular Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$136,740 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($3.25) to ($3.31) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.25 out of 5 stars

Medical Sector

308th out of 1,023 stocks

Biological Products, Except Diagnostic Industry

46th out of 170 stocks

FDMT stock logo

About 4D Molecular Therapeutics (NASDAQ:FDMT) Stock

4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1/2 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; CRF; Roche; and CFF. The company was founded in 2013 and is headquartered in Emeryville, California.

Receive FDMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 4D Molecular Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FDMT Stock News Headlines

Without Graphite, There Would Be ZERO EV Batteries!
Investors constantly hear that lithium is the key to powering the transition to green energy. Truth is, today's EV batteries contain more graphite in volume than any other essential ingredients.
4D Molecular (FDMT) Stock Up 178% in One Month: Here's Why
Without Graphite, There Would Be ZERO EV Batteries!
Investors constantly hear that lithium is the key to powering the transition to green energy. Truth is, today's EV batteries contain more graphite in volume than any other essential ingredients.
Biotech champion, QB3 leader Reg Kelly to retire
See More Headlines
Receive FDMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for 4D Molecular Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FDMT Company Calendar

Last Earnings
11/10/2021
Today
12/06/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/27/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FDMT
Fax
N/A
Employees
124
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$34.50
High Stock Price Forecast
$68.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+58.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-71,320,000.00
Net Margins
-5,331.88%
Pretax Margin
-5,331.88%

Debt

Sales & Book Value

Annual Sales
$18.04 million
Book Value
$9.93 per share

Miscellaneous

Free Float
28,758,000
Market Cap
$706.47 million
Optionable
Not Optionable
Beta
2.84

Key Executives

  • Dr. John F. Milligan Ph.D. (Age 61)
    Exec. Chairman
    Comp: $150k
  • Dr. David H. Kirn M.D. (Age 60)
    Co-Founder, CEO & Director
    Comp: $811k
  • Ms. Theresa Janke (Age 47)
    Co-Founder & Chief of Staff
    Comp: $652.32k
  • Mr. August J. Moretti Esq. (Age 71)
    J.D., Chief Financial Officer
    Comp: $587.2k
  • Dr. Fred Kamal Ph.D. (Age 59)
    Pres & COO
  • Mike Zanoni
    VP of Investor Relations
  • Dr. Scott P. Bizily J.D. (Age 50)
    Ph.D., Chief Legal & HR Officer and Corp. Sec.
  • Dr. Robert S. Fishman (Age 60)
    Chief Medical Officer & Therapeutic Area Head of Pulmonology
  • Dr. Raphael Schiffmann M.D.
    Sr. VP & Therapeutic Area Head of Cardiology
  • Dr. Robert Y. Kim M.B.A.
    M.D., Sr. VP & Clinical Therapeutic Area Head of Ophthalmology













FDMT Stock - Frequently Asked Questions

Should I buy or sell 4D Molecular Therapeutics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for 4D Molecular Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" FDMT shares.
View FDMT analyst ratings
or view top-rated stocks.

What is 4D Molecular Therapeutics' stock price forecast for 2023?

4 analysts have issued 12 month price targets for 4D Molecular Therapeutics' shares. Their FDMT share price forecasts range from $11.00 to $68.00. On average, they predict the company's stock price to reach $34.50 in the next twelve months. This suggests a possible upside of 53.7% from the stock's current price.
View analysts price targets for FDMT
or view top-rated stocks among Wall Street analysts.

How have FDMT shares performed in 2022?

4D Molecular Therapeutics' stock was trading at $21.94 on January 1st, 2022. Since then, FDMT shares have increased by 2.3% and is now trading at $22.44.
View the best growth stocks for 2022 here
.

Are investors shorting 4D Molecular Therapeutics?

4D Molecular Therapeutics saw a decline in short interest in November. As of November 15th, there was short interest totaling 2,700,000 shares, a decline of 6.9% from the October 31st total of 2,900,000 shares. Based on an average daily trading volume, of 493,600 shares, the days-to-cover ratio is currently 5.5 days.
View 4D Molecular Therapeutics' Short Interest
.

When is 4D Molecular Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 27th 2023.
View our FDMT earnings forecast
.

How were 4D Molecular Therapeutics' earnings last quarter?

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.82) earnings per share for the quarter, missing the consensus estimate of ($0.81) by $0.01. The firm had revenue of $1.37 million for the quarter. 4D Molecular Therapeutics had a negative net margin of 5,331.88% and a negative trailing twelve-month return on equity of 36.94%.

When did 4D Molecular Therapeutics IPO?

(FDMT) raised $101 million in an initial public offering on Friday, December 11th 2020. The company issued 4,800,000 shares at $20.00-$22.00 per share. Goldman Sachs, Evercore ISI and William Blair served as the underwriters for the IPO and Chardan was co-manager.

What is 4D Molecular Therapeutics' stock symbol?

4D Molecular Therapeutics trades on the NASDAQ under the ticker symbol "FDMT."

Who are 4D Molecular Therapeutics' major shareholders?

4D Molecular Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.89%), Vanguard Group Inc. (4.08%), State Street Corp (2.09%), Point72 Asset Management L.P. (0.92%), Bank of New York Mellon Corp (0.33%) and Renaissance Technologies LLC (0.21%). Insiders that own company stock include David Schaffer and Scott Bizily.
View institutional ownership trends
.

How do I buy shares of 4D Molecular Therapeutics?

Shares of FDMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 4D Molecular Therapeutics' stock price today?

One share of FDMT stock can currently be purchased for approximately $22.44.

How much money does 4D Molecular Therapeutics make?

4D Molecular Therapeutics (NASDAQ:FDMT) has a market capitalization of $726.83 million and generates $18.04 million in revenue each year. The company earns $-71,320,000.00 in net income (profit) each year or ($3.33) on an earnings per share basis.

How many employees does 4D Molecular Therapeutics have?

The company employs 124 workers across the globe.

How can I contact 4D Molecular Therapeutics?

The official website for the company is www.4dmoleculartherapeutics.com. The company can be reached via phone at 510 505 2680 or via email at mzanoni@4dmt.com.

This page (NASDAQ:FDMT) was last updated on 12/6/2022 by MarketBeat.com Staff